蒙药当归-4味散联合消炎痛治疗痛经疗效观察

目的：研究蒙西医治疗原发性痛经的临床疗效。方法：60例原发性痛经患者随机分为治疗组和对照组,治疗组用消炎痛联合用蒙药当归-4味散,对照组用消炎痛。结果：治疗组原发性痛经的总有效率为90%,对照组原发性痛经的总有效率为83.3%,治疗组优于对照组P<0.05。结论：经系统临床观察,蒙西医治疗原发性痛经疗效显著。     

威麦宁胶囊联合放疗治疗老年晚期非小细胞肺癌的临床观察

目的观察威麦宁胶囊联合三维适形放疗（3DCRT）治疗老年晚期非小细胞肺癌（NSCLC）的临床疗效及不良反应。方法168例老年NSCLC患者随机分为治疗组和对照组。每组84例,行3DCRT治疗,总剂量60～66Gy／30～33F／6—6．6W。治疗组3DCRT治疗同时予威麦宁胶囊口服,8粒／次,3次／日,服用至放疗结束后2周。2组放疗结束后60天评价疗效。结果治疗组患者的生活质量评分提高率明显高于对照组（P〈0．05）。治疗组有效率86．9％,对照组有效率73．8％（P〉0．05）;局部症状缓解改善率治疗组均明显高于对照组。治疗组放射性肺炎、放射性食管炎等放疗不良反应发生率明显低于对照组（P〈0．05）。结论威麦宁胶囊联合3DCRT治疗老年晚期NSCLC能提高临床疗效,并能减轻放射治疗不良反应,提高患者生存质量。     

张伟辨治原发性纤毛运动障碍经验

原发性纤毛运动障碍是由纤毛结构缺陷引起的多发性异常遗传病,属于临床罕见、疑难疾病。张伟老师认为本病因先天禀赋不足,肺肾亏虚,气运失司,布津不利,津聚为痰,痰凝化热导致,临床治疗以清热化痰、健脾养阴固本为法,获得良好疗效。介绍张老师临床治疗本病的经验及临床典型病案,以期对本病的辨治有所启示。     

论肺痿与支气管扩张

"肺痿"病名首见于《金匮要略》,以咳吐浊唾涎沫为主症。近年来部分学者认为肺纤维化与肺痿相对应,然而二者表现不尽相同。考证自汉以降中医文献,所载肺痿症状并不一致。仲景记述肺痿以咳吐浊唾涎沫为主要表现,与支气管扩张最为相近。仲景之后,随着疾病谱改变,医家言及肺痿,所述症状除浊唾涎沫外,尚有咯血、咳脓痰等,对应疾病与仲景所指则有所拓展,除支气管扩张外还包括肺结核、肺脓肿等。中医病名所指疾患随时代变迁多有不同,"肺痿"一病不同时期所对疾病亦不尽相同。     

四逆汤立足点在中焦

医圣仲景《伤寒论》载四逆汤一方,自古到今,众医家皆将四逆汤归入少阴救逆方,其功效皆与“回阳救逆,温阳固脱”有种种联系,皆属中规中矩之说法。余从事脾胃病的中医临床多年,对近年来兴起之火神派有较深入的研究,其中如卢崇汉、刘力红、吴佩衡、傅文录、张存悌、李可等医师,其治疗多种病症大多从四逆汤化裁,亦大剂量应用附子,其所治之病如乙肝、不孕症、复发性口疮,胃痛、巨幼细胞贫血症、带下症等,皆达到立竿见影之效,可知仅将四逆汤列入温阳救逆之方,何其谬也！对于四逆汤,笔者认为其真正的立足点在中焦脾胃,并非在肾阴肾阳,故将近年来对四逆汤的研究并结合火神派对四逆汤的认识,从四逆汤的组成、格局进行剖析,愿为四逆汤正名。     

Effects of Wei Chang An pill(胃肠安丸) on enzyme activity and levels of vasoactive peptide and substance P in the small intestine of rats with compound diarrhea

OBJECTIVE:To investigate the regulatory effects of Wei Chang An Pill(WCAP) on enzyme activity and gastrointestinal hormones in the small intestine of rats with compound diarrhea.METHODS:Forty Wistar rats were randomly divided into a control,diarrhea model,and WCAP high,medium,and low dose groups.The control group was not treated,and the model group was administered intragastric distilled water.The WCAP groups were given WCAP suspension,80,60 or 40 mg · kg-1 · d-1,for 4 days.Stool properties were observed.After the experiment,thymus and spleen indices were measured,and the activities of lactate dehydrogenase(LDH),malate dehydrogenase(MDH),and disaccharidase(lactase) in the small intestinal mucous membrane,and levels of substance P(SP) and vasoactive peptide(VIP) in the colon were determined.RESULTS:Compared with the control group,thymus and spleen indices were significantly decreased,LDH,MDH,and disaccharidase activity in the small intestine was decreased,and SP and VIP levels in the colon were significantly increased inthe diarrhea model group.Compared with the model group,thymus and spleen indices were significantly increased,and LDH,MDH,and disaccharidase activity in the small intestine and SP and VIP levels in the colon were significantly decreased in theWCAP medium dose group.CONCLUSION:The diarrhea model rats exhibited pathological changes including atrophy of the thymus and spleen,decreased enzyme activity in the small intestine,and gastrointestinal hormone disturbance.WCAP can increase the activity of intestinal digestive enzymes and regulate gastrointestinal hormones,thereby relieving diarrhea.     

异位散对子宫内膜异位症家兔的球结膜微循环及血管活性物质的影响

目的 :研究自制促乳剂 (PBP)对大鼠乳房微循环的影响和促乳机理。方法 :用微循环显微录相摄像系统及步进慢放方式观察PBP的作用。结果 :( 1)增加了乳房血流量和微血管血流速度。 ( 2 )使乳头乳腺微血管管径一直维持在 2 4.4± 0 .2 8μm ,而对照组为 4.6± 0 .2 1μm。 ( 3)乳头乳腺微血管密度PBP组显著高于对照组 (P <0 .0 1)。( 4)乳头微血管构型由树枝型转为网囊型。镜下可见二组均为线流 ,偶见白细胞闪烁而过。 ( 5 )乳鼠体重在出生 0h二组无差异 (P >0 .0 5 )。结论 :PBP对大鼠乳房有正向调节作用 ,可促进乳汁分泌。泌乳机理是通过对乳房微血管构型的改变 ,增加了单位面积的微血管数目、管径 ,从而使乳房微血管血流量增多。目的 :探讨中药治疗子宫内膜异位症的作用机理。方法 :通过复制动物模型进行研究。结果 :发现子宫内膜异位症家兔的球结膜微循环出现明显障碍 ,经异位散治疗 ,其球结膜微循环的状况得到明显改善 ,由于异位内膜所致的上升的 6 酮 前列环素1α、血栓烷素B2 水平明显降低。结论 :实验揭示了异位散治疗家兔子宫内膜异位症机理与微循环的改善与血管活性物质水平下降有关。     

五味消栓口服液治疗脑梗塞临床研究

目的;观察五味消栓口服液治疗脑梗塞的临床疗效,方法：治疗组300例采用五味消栓口服液治疗,每次10ml,每日3次口服,对照组100例采用消栓口服液,每次10ml,每日3次了,均1个月为1疗程,单盲给药,结果：本药总有效率91．33％,愈显率53％,能显著改善中医药临床症状和神经功能缺损,显著改善血流液变学各项观察指标,并且无明显毒副作用,结论：提示五味消栓口服液对脑硬塞确有疗效。     

脑血通口服液治疗缺血性中风的临床研究

采用脑血通口服液缺血性中风,并与服用脑血康口服液的对照组相比较,临床观察表明：脑血通口服液对缺血性中风的神经功能改善以及降低血脂、血压、血糖、血液粘度、红细胞压积具有显著疗效,有效率达93．41％,与对照组相比有显著性差异（P＜0．05）。     

Incidence and risk factors for retrograde type A dissection and stent graft-induced new entry after thoracic endovascular aortic repair

Objective

Stent graft (SG)-induced new entry (SINE) and retrograde type A dissection (RTAD) are serious device-related complications occurring after thoracic endovascular aortic repair (TEVAR) for Stanford type B aortic dissection (TBAD) and may lead to endograft-related complications including retrograde dissection and death. The purpose of this study was to investigate the incidence and risk factors for the development of RTAD and SINE after TEVAR for TBAD and to identify the complications associated with this.